Hum Immunol. 2009 Jun;70(6):413-6. Epub 2009 Mar 9.

Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products.

Coppage M, Baker M, Fialkow L, Meehan D, Gettings K, Chen L, Massey HT, Blumberg N.

Source

Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Strong Memorial Hospital, Rochester, NY, USA. myra_coppage@urmc.rochester.edu

Abstract

Ventricular assist devices provide support for a failing heart and often serve as a bridge to transplantation. The use of these devices has also been associated with allosensitization to HLA antigens because of transfusion of blood products. Our program established a protocol mandating the use of leukoreduced, irradiated and ABO identical products, including platelets, in patients receiving initial implantations of VADs as a bridge to transplantation. Recipients were tested for anti-HLA antibodies before VAD implantation and monthly post-implantation by cytotoxicity and solid phase assays. We observed minimal de novo anti-HLA sensitization (<10%) in this population of 55 patients, each receiving a mean of 90 blood components, using this approach. No patient developed broad sensitization (PRA>50%). In conclusion, The use of leukoreduced, irradiated, ABO identical blood products abrogates broad allosensitization in this highly transfused population.

PMID:: 19275923; [PubMed - indexed for MEDLINE]

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Blood Transfusion and Donation - MedlinePlus Health Information

Supplemental Content

Related citations

Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions. [J Thorac Cardiovasc Surg. 2007]
Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions.
Drakos SG, Stringham JC, Long JW, Gilbert EM, Fuller TC, Campbell BK, Horne BD, Hagan ME, Nelson KE, Lindblom JM, et al. J Thorac Cardiovasc Surg. 2007 Jun; 133(6):1612-9.
Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization. [J Heart Lung Transplant. 1999]
Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization.
Stringham JC, Bull DA, Fuller TC, Kfoury AG, Taylor DO, Renlund DG, Karwande SV. J Heart Lung Transplant. 1999 Feb; 18(2):160-5.
Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients. [Ann Thorac Surg. 2006]
Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients.
Drakos SG, Kfoury AG, Long JW, Stringham JC, Fuller TC, Nelson KE, Campbell BK, Gilbert EM, Renlund DG. Ann Thorac Surg. 2006 Sep; 82(3):889-93.
Review Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients. [Contrib Nephrol. 2009]
Review Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients.
Jordan SC, Peng A, Vo AA. Contrib Nephrol. 2009; 162:13-26. Epub 2008 Oct 31.
Review New paradigms in the management of alloimmune refractoriness to platelet transfusions. [Curr Opin Hematol. 2007]
Review New paradigms in the management of alloimmune refractoriness to platelet transfusions.
Vassallo RR Jr. Curr Opin Hematol. 2007 Nov; 14(6):655-63.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Lack of significant de novo HLA allosensitization in ventricular assist device r...
Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products.
Hum Immunol. 2009 Jun ;70(6):413-6. Epub 2009 Mar 9 .

PubMed
Cutting edge: CD4+ T cell-derived IL-2 is essential for help-dependent primary C...
Cutting edge: CD4+ T cell-derived IL-2 is essential for help-dependent primary CD8+ T cell responses.
J Immunol. 2008 Dec 1 ;181(11):7445-8.

PubMed
p21-Activated kinase 1 coordinates aberrant cell survival and pericellular prote...
p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer.
Neoplasia. 2008 Apr ;10(4):314-29.

PubMed
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus...
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.
Br J Cancer. 2009 Jan 27 ;100(2):315-21. Epub 2009 Jan 6 .

PubMed
Fibrous dysplasia.
Fibrous dysplasia.
J Am Acad Orthop Surg. 2004 Sep-Oct ;12(5):305-13.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: